Plant Name: Carthamus tinctorius
Taxonomic Information:
Plant ID: NPO18311
Plant Latin Name: Carthamus tinctorius
Taxonomy Genus: Carthamus
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
4222
Plant-of-the-World-Online:
324467-2
Used in Medicines:
Country/Region:
Philippines; Indonesia; India; China; Jordan; Thailand; South KoreaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; Kampo; TCMGeographical Distribution:
Canada; Afghanistan; Italy; Bangladesh; Kuwait; Cambodia; Ethiopia; Ireland; Laos; Argentina; Thailand; Saudi Arabia; Australia; Iran; Algeria; Turkey; Jordan; Chile; China; Poland; Spain; Ukraine; Eritrea; Netherlands; Libya; Oman; Philippines; Indonesia; United States; Morocco; Uruguay; Hungary; New Zealand; Yemen; Russia; Romania; Myanmar; Mexico; Egypt; South Africa; India; United Kingdom; Tunisia; Austria; Vietnam; Paraguay; Japan; South Korea
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; FFAR1; FFAR4; | |
| TSHR; NPSR1; | |
| CDA; ADK; ALOX12; HSD17B2; HSD17B10; NOX4; ALOX15; POLB; | |
| ACHE; | |
| AXL; FLT3; CDK1; PIM1; MET; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA7; CA4; | |
| PPARA; | |
| RXRA; | |
| TYR; | |
| KDM4E; | |
| MMP9; MMP1; MMP2; | |
| AHR; NFKB1; | |
| FUT7; | |
| LMNA; FABP3; FABP5; FABP4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 2 group B | RXRA | Retinoid X receptor alpha | P19793 | CHEMBL2061 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.442E-08 | 3.945E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 4.601E-08 | 5.009E-05 | ADORA1, ADORA2A, ALOX12, AURKB, AXL, CDK1, FFAR4, IGF1R, KDR, LMNA, MMP9, NFKB1, PIM1 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 4.108E-07 | 2.631E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 4.337E-07 | 2.672E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 5.861E-07 | 3.191E-04 | AXL, CA2, CYP1A1, CYP1A2, FABP3, FFAR1, FLT3, HSD17B2, NFKB1, RXRA, TYR |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 9.828E-07 | 4.977E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.228E-06 | 5.815E-04 | ADORA1, ADORA2A, ADORA3, AHR, AXL, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, PPARA, RXRA, TSHR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.402E-06 | 6.387E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.433E-06 | 6.387E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 1.974E-06 | 8.267E-04 | ACHE, AXL, CA2, CDK1, CYP1A1, CYP1A2, FLT3, HSD17B2, KDR, POLB, PPARA, RXRA, TYR |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 2.174E-06 | 8.932E-04 | ACHE, ADORA1, ADORA2A, CYP1A1, CYP1B1, FFAR1, FFAR4, HSD17B2, NFKB1 |
| BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 2.604E-06 | 1.050E-03 | ALOX15, AXL, CYP1A1, CYP1B1, FABP4, FFAR4, FLT3, IGF1R, KDR, MMP2, NFKB1, NOX4, TSHR |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.259E-06 | 1.248E-03 | CA12, CA2, CA4, CA7 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 3.325E-06 | 1.248E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 3.514E-06 | 1.275E-03 | ACHE, ADORA3, ALOX15, CDK1, CYP1A1, PPARA |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.571E-06 | 1.275E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 5.180E-06 | 1.560E-03 | ADORA2A, CA2, CDK1, CYP1A1, CYP1A2, CYP1B1, FLT3, NFKB1, NOX4, TYR |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.307E-06 | 1.560E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.307E-06 | 1.560E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 6.924E-06 | 1.908E-03 | ADORA1, ADORA2A, FFAR4, NFKB1, PPARA |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 8.325E-06 | 2.210E-03 | ADORA1, ADORA2A, CA2, CA7, KDR, NPSR1 |
| BP | GO:0051179; localization | GO:0006909; phagocytosis | 1.139E-05 | 2.819E-03 | ADORA1, ADORA2A, ALOX15, AXL |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.379E-05 | 3.300E-03 | CA12, CA2, CA4, CA7, CDA, MMP1, MMP2, MMP9, PPARA, RXRA |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.526E-05 | 3.462E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.590E-05 | 3.462E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.590E-05 | 3.462E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.590E-05 | 3.462E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.590E-05 | 3.462E-03 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0019216; regulation of lipid metabolic process | 1.917E-05 | 3.976E-03 | ADORA1, CYP1A1, FABP3, FLT3, NFKB1, PPARA, RXRA |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.025E-05 | 4.084E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.025E-05 | 4.084E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0051262; protein tetramerization | 2.280E-05 | 4.393E-03 | ACHE, CDA, HSD17B10, IGF1R, RXRA |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.622E-05 | 4.797E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.882E-05 | 5.186E-03 | ADORA1, CYP1A1, LMNA, MMP2, NOX4, PPARA |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.175E-05 | 5.459E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 3.245E-05 | 5.520E-03 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1, HSD17B10, HSD17B2, KDM4E, NOX4, TYR |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.424E-05 | 5.656E-03 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0016042; lipid catabolic process | 3.637E-05 | 5.948E-03 | ADORA1, CYP1A2, CYP1B1, FABP3, FABP4, FABP5 |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 5.092E-05 | 7.595E-03 | ALOX12, CA12, CA2, CA7, FABP3, FABP4, FFAR1, MET, NOX4, NPSR1 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 5.283E-05 | 7.773E-03 | ALOX12, ALOX15 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 6.484E-05 | 9.289E-03 | ADORA1, ADORA2A, ADORA3, AXL, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, TSHR |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 7.013E-05 | 9.485E-03 | AXL, FLT3, IGF1R, KDR, MET |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 9.893E-09 | 1.326E-06 | FABP3, RXRA, FABP4, FABP5, MMP1, PPARA |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.547E-06 | 9.968E-05 | RXRA, FLT3, MMP1, MMP2, MET, MMP9, NFKB1, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 5.208E-08 | 3.490E-06 | CA12, CA2, CA4, CA7 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.774E-06 | 1.280E-04 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.976E-06 | 9.968E-05 | RXRA, FLT3, MMP9, MET, NFKB1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.681E-06 | 1.939E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 9.007E-05 | 1.432E-03 | MMP2, KDR, MMP9, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 8.200E-05 | 1.432E-03 | ADORA2A, ADORA1, PPARA, NFKB1, TSHR |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 9.921E-05 | 1.432E-03 | CYP1A2, CYP1A1, CYP1B1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 3.489E-04 | 3.597E-03 | CDA, FUT7, HSD17B2, CYP1A2, ALOX15, CYP1A1, ADK, ALOX12, TYR, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.069E-04 | 1.432E-03 | MMP1, MMP2, MMP9 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.861E-04 | 3.194E-03 | FLT3, PIM1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 2.714E-04 | 3.194E-03 | FABP4, ADORA1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 5.245E-04 | 4.686E-03 | PIM1, CYP1B1, MMP9, MET, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 9.769E-04 | 7.273E-03 | RXRA, KDR, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 5.244E-04 | 4.686E-03 | RXRA, PPARA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.279E-03 | 8.567E-03 | ADORA2A, KDR, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.930E-04 | 4.966E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.521E-03 | 9.703E-03 | MMP2, PIM1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.325E-04 | 6.562E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.215E-03 | 8.567E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ACHE; ADORA3; MMP9; MMP2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; MMP9; CDA; MMP2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; ADORA2A; ADK; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; TYR; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| NA: NA | Edema | NA | CA2; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; FFAR1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Cutaneous T-cell lymphoma | C84.0, C84.1 | RXRA; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
